

(51) International Patent Classification:
C07K 14/575 (2006.01)(21) International Application Number:
PCT/US2020/049244(22) International Filing Date:
03 September 2020 (03.09.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/895,201	03 September 2019 (03.09.2019)	US
62/983,515	28 February 2020 (28.02.2020)	US
63/020,945	06 May 2020 (06.05.2020)	US
63/059,747	31 July 2020 (31.07.2020)	US

(71) Applicant: **PROTAGONIST THERAPEUTICS, INC.**
[US/US]; 7707 Gateway Boulevard, Suite 140, Newark,
California 94560-1160 (US).

(72) Inventors: **LIU, David Y.**; c/o Protagonist Therapeutics,
Inc., 7707 Gateway Boulevard, Suite 140, Newark, Cal-
ifornia 94560-1160 (US). **BOURNE, Gregory Thomas**;
19 Greenwood Close, Moggill, Brisbane, Queensland 4070
(AU). **TARANATH, Roopa**; 22641 Queens Oak Court,
Cupertino, California 95014 (US). **GUPTA, Suneel Ku-**
mar; 1331 Elsona Drive, Sunnyvale, California 94087

(US). **MODI, Nishit Bachulal**; 587 Torland Court, Sunny-
vale, California 94087 (US).

(74) Agent: **LAHERTY, Carol et al.**; Cooley LLP, 1299 Penn-
sylvania Avenue, NW, Suite 700, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: CONJUGATED HEPCIDIN MIMETICS




FIG. 1A

(57) Abstract: The present invention provides hepcidin analogues, and related pharmaceutical compositions and use thereof in treating polycythemia vera.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*